Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PEBPP
ADC Name
LC A032D/HC G056K
Synonyms
LC-A032D/HC-G056K
   Click to Show/Hide
Organization
BioAtla, Inc.
Drug Status
Investigative
Antibody Name
BA-130-03-05
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
LC A032D/HC G056K linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 100
%
BT-474 cells
Invasive breast carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
BT-474 cells
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive HER2 expression (EPHA2+++/++)
Method Description
To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model BT474 CDX model
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100% Positive HER2 expression (EPHA2+++/++)
Method Description
To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model BT474 CDX model
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
References
Ref 1 Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof; 2021-07-29.